Adribin is a core component of many standard multi-drug protocols (for example ABVD for Hodgkin lymphoma, CHOP for non-Hodgkin lymphoma, and AC/EC regimens for early and advanced breast cancer). In these settings it is used together with other cytotoxic agents rather than as monotherapy.

Off-Label Use

Adribin is sometimes used off-label, at the discretion of the treating oncologist, in other soft-tissue and rare tumor types where anthracycline-based chemotherapy is considered beneficial. Such use should only occur under specialist oncology supervision.

Composition

Each vial of Doxorubicin Hydrochloride for injection contains Doxorubicin Hydrochloride as the active ingredient, equivalent to a stated amount of doxorubicin base.

Injection (ready-to-use solution): commonly available as 2 mg/mL solution in vials of 10 mg/5 mL, 50 mg/25 mL, and 200 mg/100 mL.
Powder for reconstitution (lyophilized): commonly available as 10 mg, 50 mg, and 150 mg vials.

Strength and pack size vary by manufacturer; the prescribing physician and dispensing pharmacist should confirm the exact product strength before administration.

Description

Adribin is a cytotoxic anthracycline antibiotic derived from Streptomyces peucetius var. caesius. It is used intravenously as part of chemotherapy regimens for a wide range of hematologic and solid tumor malignancies.

Adribin works by intercalating into DNA and inhibiting topoisomerase II, which disrupts DNA synthesis and repair in rapidly dividing cancer cells. It is administered only by, or under the direct supervision of, a physician experienced in the use of cytotoxic chemotherapy, because of its narrow therapeutic index and significant toxicity profile, including cumulative dose-dependent cardiotoxicity.

Therapeutic Class

Antineoplastic anthracycline antibiotic (cytotoxic chemotherapy agent); Adribin belongs to this class.

Pharmacology

Mechanism of Action

Doxorubicin Hydrochloride exerts its cytotoxic effect through several mechanisms:

Intercalation between DNA base pairs, distorting the DNA helix and blocking DNA and RNA synthesis.
Inhibition of topoisomerase II, stabilizing the DNA-topoisomerase II complex and causing DNA strand breaks.
Generation of reactive oxygen species (free radicals), which contributes to its antitumor activity but is also the principal mechanism believed to underlie its cumulative, dose-dependent cardiotoxicity.

Pharmacokinetics

Doxorubicin Hydrochloride is administered intravenously (it is not orally bioavailable). It is extensively distributed into tissues, undergoes hepatic metabolism (primarily to the active metabolite doxorubicinol), and is eliminated mainly via biliary/fecal excretion, with a small renal component. Clearance is reduced in hepatic impairment, requiring dose adjustment.

Dosage & Administration of Adribin

General Principles

Adribin must be prescribed and administered only under the supervision of a physician experienced in cytotoxic chemotherapy. Dose is calculated based on body surface area (BSA) and adjusted according to protocol, hematologic status, hepatic function, and cumulative lifetime dose already received.

Typical Adult Dosing by Regimen

Regimen	Typical Dose
Single-agent	60–75 mg/m² IV as a single dose every 21 days
Combination therapy	40–60 mg/m² IV every 21–28 days, or 20–30 mg/m² on days 1–3 every 3–4 weeks, per specific protocol
Weekly schedule	20 mg/m² IV once weekly (used in select regimens)

Pediatric Dosing

Dosing in children is protocol-specific and based on body surface area (or body weight in infants), following recognized pediatric oncology treatment protocols (e.g., for acute leukemias, Wilms' tumor, neuroblastoma, and sarcomas). Cardiac monitoring is especially important given lifelong cumulative dose exposure starting at a young age.

Cumulative Dose Limit

Total cumulative lifetime dose should generally not exceed 550 mg/m² (or 450 mg/m² in patients who have received prior mediastinal/chest irradiation or concomitant potentially cardiotoxic therapy such as cyclophosphamide or trastuzumab), because of the sharply rising risk of irreversible cardiomyopathy beyond this threshold.

Hepatic Impairment Dose Adjustment

Serum Bilirubin	Dose Reduction
1.2–3 mg/dL	Reduce dose by 50%
>3 mg/dL	Reduce dose by 75%

Administration

Adribin is given by slow intravenous injection into the tubing of a freely running IV infusion, or as a short IV infusion, over several minutes. It must never be given intramuscularly or subcutaneously. Extreme care must be taken to confirm a fully patent IV line, since extravasation causes severe local tissue necrosis (see Precautions and Warnings).

Administration of Adribin

Adribin is for intravenous use only and must be administered by a healthcare professional experienced with cytotoxic agents. It is given as a slow IV push into a free-flowing IV line or as a short infusion; it must never be injected intramuscularly or subcutaneously. Because Adribin is a vesicant, the IV line must be checked for patency before and during administration, and the infusion stopped immediately if extravasation is suspected.

Interaction of Adribin

Clinically Significant Drug Interactions

Other cardiotoxic agents (e.g., trastuzumab, other anthracyclines, high-dose cyclophosphamide): Concomitant or sequential use increases the risk of cardiotoxicity; cardiac function should be monitored more closely.
Hepatotoxic drugs: Drugs that impair hepatic function can reduce clearance of Adribin, increasing systemic toxicity; dose adjustment based on liver function may be needed.
Cyclophosphamide: Combination increases the risk of hemorrhagic cystitis and myelosuppression.
Live or live-attenuated vaccines: Should be avoided during Adribin therapy because of immunosuppression, which can result in serious or fatal infection from the vaccine strain.
Radiation therapy: Adribin can cause a "radiation recall" reaction at previously irradiated sites, and concurrent radiation increases both cardiac and local tissue toxicity.
Other myelosuppressive drugs: Additive bone marrow suppression; blood counts should be monitored closely.

Contraindications

Doxorubicin Hydrochloride is contraindicated in patients with:

Known hypersensitivity to Doxorubicin Hydrochloride or other anthracyclines.
Severe myocardial insufficiency or severe pre-existing cardiac disease.
Recent myocardial infarction.
Severe cardiac arrhythmias.
Prior treatment with maximum cumulative doses of Doxorubicin Hydrochloride or other anthracyclines/anthracenediones.
Severe hepatic impairment.
Persistent, severe myelosuppression from prior cytotoxic therapy or radiotherapy.

Side Effects of Adribin

Very Common

Myelosuppression (leukopenia, neutropenia, thrombocytopenia, anemia) — usually dose-limiting
Alopecia (hair loss), often complete but reversible after treatment
Nausea and vomiting
Mucositis / stomatitis
Red-orange discoloration of urine for 1–2 days after dosing (harmless)

Common

Fatigue, anorexia, diarrhea
Skin hyperpigmentation, nail changes

Serious (see also Precautions and Warnings)

Cumulative, dose-dependent cardiotoxicity, including arrhythmias and delayed, potentially irreversible cardiomyopathy/heart failure
Severe local tissue necrosis if extravasation occurs during administration
Secondary malignancies, including secondary acute myeloid leukemia
Severe infection due to neutropenia
Tumor lysis syndrome in patients with large tumor burden

Pregnancy & Lactation

Adribin can cause fetal harm when administered to a pregnant woman, based on its mechanism of action and animal reproduction data. Adribin should not be used during pregnancy unless the potential benefit to the mother clearly justifies the potential risk to the fetus, and only after full discussion with the treating physician. Women of reproductive potential should use effective contraception during and for a period after treatment.

Adribin is excreted into human breast milk. Because of the potential for serious adverse reactions in a breastfeeding infant, breastfeeding should be discontinued before starting treatment and should not be resumed without consulting the physician.

Precautions & Warnings

Boxed Warnings

Cardiotoxicity: Adribin can cause cumulative, dose-dependent cardiotoxicity, including acute arrhythmias and delayed cardiomyopathy/congestive heart failure that may appear months to years after treatment and can be irreversible. Baseline and periodic monitoring of left ventricular ejection fraction (LVEF) by echocardiogram or MUGA scan is required, and cumulative lifetime dose must be tracked.
Myelosuppression: Severe bone marrow suppression can occur; complete blood counts must be monitored before and during each cycle.
Extravasation and tissue necrosis: Adribin is a vesicant. Extravasation can cause severe local tissue damage and necrosis. It must be administered only into a securely, freely-flowing intravenous line by personnel trained in cytotoxic drug administration.
Secondary malignancies: Secondary acute myeloid leukemia and myelodysplastic syndrome have been reported, usually years after treatment, particularly when combined with DNA-damaging antineoplastic agents or radiotherapy.
Administration: Adribin must be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapeutic agents, and only via the intravenous route.

Additional Precautions

Use with caution and reduced dose in hepatic impairment (see Dosage and Administration).
Monitor for hyperuricemia and tumor lysis syndrome, especially in patients with high tumor burden (e.g., leukemia, lymphoma).
Radiation recall reactions can occur at sites of previous irradiation.
Immunosuppression increases susceptibility to infection; avoid live vaccines during therapy.

Overdose Effects of Adribin

Acute overdose of Adribin can cause severe myelosuppression (with risk of serious infection and bleeding), severe mucositis/gastrointestinal toxicity, and acute cardiac toxicity that may manifest within 24 hours. Delayed cardiomyopathy may also occur weeks after an overdose.

There is no specific antidote. Suspected overdose is a medical emergency — the patient should be taken immediately to a hospital or seek emergency medical attention, where supportive care (including hospitalization, cardiac monitoring, blood product support, and treatment of infection) can be provided. Do not attempt to manage a suspected Adribin overdose at home.

Storage Conditions

Store Adribin injection under refrigeration (2°C to 8°C), protected from light, in the original carton until time of use, unless the specific product labeling states otherwise. Do not freeze. Keep out of reach of children. Adribin should be handled and disposed of according to institutional cytotoxic drug handling procedures.

Use In Special Populations

Elderly

Elderly patients may be at increased risk of Adribin-related cardiotoxicity and myelosuppression; closer cardiac and hematologic monitoring is recommended, and dose modification may be considered.

Hepatic Impairment

Dose reduction is required based on serum bilirubin, as Adribin is cleared primarily by the liver (see Dosage and Administration).

Renal Impairment

No formal dose adjustment is established for renal impairment alone; use with caution and clinical judgment.

Pediatric Use

Adribin is used in established pediatric oncology protocols (e.g., acute leukemias, Wilms' tumor, neuroblastoma, sarcomas) with weight/BSA-based dosing. Long-term cardiac follow-up is important because children treated with Adribin remain at risk of late-onset cardiotoxicity into adulthood.

Duration Of Treatment

Duration of Adribin therapy is determined by the treating oncologist based on the specific cancer type, chemotherapy protocol, response to treatment, and cumulative dose already administered. Treatment is typically given in cycles (commonly every 3–4 weeks) for a pre-specified number of cycles, and is stopped earlier if the lifetime cumulative dose limit is approached or if unacceptable toxicity (especially cardiac) develops.

Reconstitution

Lyophilized powder formulations of Adribin for injection must be reconstituted before use, typically with 0.9% Sodium Chloride Injection or Sterile Water for Injection, to achieve a final concentration commonly around 2 mg/mL, according to the specific product's package insert. The reconstituted solution should be inspected visually for particulate matter and discoloration before administration and used within the time period specified by the manufacturer. Ready-to-use liquid formulations of Adribin do not require reconstitution. Reconstitution and handling must be performed by trained personnel using appropriate cytotoxic drug safety precautions.

Drug Classes

Doxorubicin Hydrochloride belongs to the anthracycline class of antineoplastic (cytotoxic) antibiotics, a subclass of DNA-damaging chemotherapy agents.

Mode Of Action

Doxorubicin Hydrochloride acts by intercalating into DNA, inhibiting topoisomerase II (causing DNA strand breaks and preventing religation), and generating reactive oxygen species that damage cellular macromolecules. These combined effects block DNA replication and transcription in rapidly dividing tumor cells, leading to cell death, while also contributing to its characteristic cardiotoxicity.

Pregnancy

Pediatric Uses

Adribin is used in children as part of established combination chemotherapy protocols for malignancies such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, and soft tissue sarcomas/osteosarcoma. Dosing is calculated by body surface area (or body weight in infants) according to the specific pediatric oncology protocol being followed. Safety and efficacy outside recognized pediatric oncology protocols have not been established. Because of the risk of cumulative, potentially delayed cardiotoxicity, children treated with Adribin require long-term cardiac follow-up well into adulthood.

Frequently Asked Questions

Q: What is Adribin 2 mg/ml IV Infusion used for?

A: Adribin 2 mg/ml IV Infusion is a chemotherapy medicine used, usually in combination with other anticancer drugs, to treat cancers such as leukemias, lymphomas, sarcomas, and breast, ovarian, bladder, and other cancers.

Q: How is Adribin 2 mg/ml IV Infusion given?

A: Adribin 2 mg/ml IV Infusion is given only by intravenous injection or infusion by trained healthcare staff, into a securely running IV line. It is never given by mouth, into a muscle, or under the skin.

Q: What is the most serious risk with Adribin 2 mg/ml IV Infusion?

A: The most serious risks are heart damage (cardiotoxicity) that is related to the total lifetime dose received and can appear months or years later, and severe drops in blood cell counts that increase the risk of infection and bleeding. Your doctor will monitor your heart function and blood counts before and during treatment.

Q: Can Adribin 2 mg/ml IV Infusion be used during pregnancy or breastfeeding?

A: Adribin 2 mg/ml IV Infusion should not be used during pregnancy unless your doctor decides the benefit clearly outweighs the risk to the baby, because it can cause fetal harm. Breastfeeding should be stopped before starting Adribin 2 mg/ml IV Infusion and should not restart without your doctor's advice.

Q: Why does my urine turn red-orange after treatment?

A: Adribin 2 mg/ml IV Infusion and its metabolites are excreted in urine, which can cause a harmless red-orange discoloration for one to two days after each dose. This is expected and not a cause for concern.

Q: What should I do if I think a dose was too high or there was an overdose?

A: An overdose or suspected overdose of Adribin 2 mg/ml IV Infusion is a medical emergency. Seek immediate medical attention or contact emergency services, as it can cause severe drops in blood counts and serious heart problems that require hospital care.

Disclaimer

The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.